Clinical Study
Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
Table 1
Baseline characteristics.
| | Patients () |
| | Median age (range) | 70 (51–87) |
| | Race | Caucasian 9 (60%)
African American 6 (40%) |
| | Performance status | Zero 9 (60%)
One 6 (40%) |
| | Prior local treatment | Prostatectomy 3 (20%);
radiation 14 (93%);
cryotherapy 1 (7%) |
| | Other prior therapies | Antiandrogen 13 (86%)
Ketoconazole 3 (20%)
Steroid 2 (13%) |
| | Gleason score | Six 4 (27%);
seven 4 (27%),
eight 1 (7%),
nine 6 (40%) |
| | Median pretreatment PSA [ng/mL] (range) | 27 (2.6–104) | | Median Hgb [g/dL] (range) | 12.9 (9.9–15.5) |
|
|
